Managers / Q3 2023
Atlas Venture Associates IX, LLC
CIK 0001671207 · 56 WAREHAM STREET, FLOOR 3, BOSTON, MA, 02118 · 617-588-2694
Summary
Atlas Venture Associates Ix, LLC reported $12M in U.S.-listed holdings across 6 positions for Q3 2023.
The portfolio is heavily concentrated: Skillz alone accounts for 49.7% of reported value.
Compared with Q2 2023, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 50.3% · $6M
- Other · 49.7% · $6M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CHRSCOHERUS BIOSCIENCES INC | NEW | +568.4K | 568.4K | +$2M | $2M |
| SYBXSYNLOGIC INC | NEW | +176.8K | 176.8K | +$496,802 | $496,802 |
| SURFACE ONCOLOGY INC | SOLD OUT | −2.95M | 0 | −$3M | $0 |
| SYNLOGIC INC | SOLD OUT | −2.65M | 0 | −$1M | $0 |
| SKILLZ INC | HELD | +0 | 1.15M | −$5M | $6M |
| SNAPSNAP INC | HELD | +0 | 150.2K | −$439,968 | $1M |
| SPROSPERO THERAPEUTICS INC | HELD | +0 | 1.35M | −$324,792 | $2M |
| NTLAINTELLIA THERAPEUTICS INC | HELD | +0 | 10.0K | −$91,600 | $316,200 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SKILLZ INC | COM | 49.69% | $6M | 1.15M |
| 2 | CHRSCOHERUS BIOSCIENCES INChistory → | COM | 18.08% | $2M | 568.4K |
| 3 | SPROSPERO THERAPEUTICS INChistory → | COM | 13.93% | $2M | 1.35M |
| 4 | SNAPSNAP INChistory → | CL A | 11.38% | $1M | 150.2K |
| 5 | SYBXSYNLOGIC INChistory → | COM | 4.23% | $496,802 | 176.8K |
| 6 | NTLAINTELLIA THERAPEUTICS INChistory → | COM | 2.69% | $316,200 | 10.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2023 | $12M | 6 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $18M | 6 | Aug 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $21M | 6 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $20M | 6 | Jan 31, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $34M | 6 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $44M | 7 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $109M | 7 | May 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $229M | 7 | Jan 27, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $301M | 7 | Nov 4, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $568M | 7 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $595M | 7 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $631M | 7 | Feb 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $97M | 6 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $94M | 6 | Aug 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $47M | 6 | May 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $57M | 6 | Feb 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $61M | 7 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $94M | 7 | Aug 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 7 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $87M | 7 | Feb 6, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.